Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Genital Neoplasms, Male 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Adrenal Cortex Hormones × 90 days × Clear all
NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT06780085 2026-05-26

MK-3475-01H

Merck Sharp & Dohme LLC

Phase 2 Recruiting
96 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡